Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iroxanadine (BRX-005) 是一种新型小分子MAPK p38 抑制剂,诱导p38 SAPK 的磷酸化,在用去氧肾上腺素预先收缩的豚鼠肺动脉制剂中诱导浓度依赖性松弛,可用于治疗动脉粥样硬化、糖尿病血管病,微血管心绞痛和外周动脉疾病等血管疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 990 | 现货 | ||
5 mg | ¥ 2,470 | 现货 | ||
10 mg | ¥ 3,700 | 现货 | ||
25 mg | ¥ 5,970 | 现货 | ||
50 mg | ¥ 8,260 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
500 mg | ¥ 22,300 | 现货 |
产品描述 | Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 번호13480-84-5 |
体内活性 | Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.[1] |
别名 | BRX005, BRX-235, BRX-005, BRX235, BRX 005, BRX 235 |
分子量 | 260.33 |
分子式 | C14H20N4O |
CAS No. | 203805-20-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (172.86 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.8413 mL | 19.2064 mL | 38.4128 mL | 96.032 mL |
5 mM | 0.7683 mL | 3.8413 mL | 7.6826 mL | 19.2064 mL | |
10 mM | 0.3841 mL | 1.9206 mL | 3.8413 mL | 9.6032 mL | |
20 mM | 0.1921 mL | 0.9603 mL | 1.9206 mL | 4.8016 mL | |
50 mM | 0.0768 mL | 0.3841 mL | 0.7683 mL | 1.9206 mL | |
100 mM | 0.0384 mL | 0.1921 mL | 0.3841 mL | 0.9603 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Iroxanadine 203805-20-3 MAPK p38 MAPK BRX005 BRX-235 BRX-005 BRX235 BRX 005 BRX 235 Inhibitor inhibitor inhibit